Lung Cancer

Glendale, AZ

164 Lung Cancer Trials near Glendale, AZ

Power is an online platform that helps thousands of Lung Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CRX100 for Solid Cancers

Scottsdale, Arizona
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with monotherapy dose escalation followed by combination cohorts.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

60 Participants Needed

9-ING-41 for Advanced Cancers

Phoenix, Arizona
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

350 Participants Needed

Dostarlimab for Advanced Cancer

Scottsdale, Arizona
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

740 Participants Needed

DF9001 + Nivolumab for Solid Tumors

Phoenix, Arizona
This trial is testing a new molecule that helps the immune system attack cancer cells. It focuses on patients with solid tumors that have a protein called EGFR. The study will determine the best dose and test its effectiveness alone and with another drug called pembrolizumab. AM0010 has been previously tested in combination with pembrolizumab for advanced cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

242 Participants Needed

Avelumab for Cancer

Scottsdale, Arizona
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

205 Participants Needed

WTX-124 + Pembrolizumab for Solid Tumors

Scottsdale, Arizona
This trial tests a new medicine called WTX-124, alone and with pembrolizumab, in patients with severe forms of skin and kidney cancer. WTX-124 helps the immune system attack cancer cells, and pembrolizumab makes it easier for the immune system to see these cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

150 Participants Needed

IMC-F106C Combinations for Solid Cancers

Scottsdale, Arizona
This trial tests IMC-F106C, a treatment that helps the immune system target and kill cancer cells in adults with advanced cancers. It guides immune cells to attack cancer cells more effectively.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

727 Participants Needed

TSR-022 for Cancer

Phoenix, Arizona
This trial is testing TSR-022, a new medicine that helps the immune system fight cancer by blocking a protein called TIM-3. TIM-3 has gained prominence as a potential candidate for cancer immunotherapy, where it has been shown that blocking TIM-3 with other treatments enhances the body's ability to fight tumors and suppress their growth. It targets patients with tumors, especially those who may not respond to standard treatments. The goal is to see if this medicine can help the immune system better attack cancer cells.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

447 Participants Needed

NDI-101150 + Pembrolizumab for Cancer

Scottsdale, Arizona
This trial is testing a new drug called NDI-101150, alone or with pembrolizumab, in adults with advanced cancers. It aims to find the safest dose and see how well it works. Pembrolizumab helps the immune system attack cancer cells and is used to treat various cancers.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

106 Participants Needed

FOG-001 for Cancer

Scottsdale, Arizona
This trial is testing FOG-001, a new medicine, to see if it is safe and effective for patients with advanced or spreading solid tumors. FOG-001 works by blocking certain proteins to stop cancer cells from growing.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

480 Participants Needed

Dato-DXd + Pembrolizumab for Non-Small Cell Lung Cancer

Chandler, Arizona
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1170 Participants Needed

Dato-DXd + Pembrolizumab for Advanced Lung Cancer

Chandler, Arizona
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

740 Participants Needed

Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer

Chandler, Arizona
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

705 Participants Needed

DS-1062a for Lung Cancer

Phoenix, Arizona
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

137 Participants Needed

Dato-DXd + Pembrolizumab for Lung Cancer

Scottsdale, Arizona
This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

145 Participants Needed

Chemoradiation + Pembrolizumab/Olaparib for Small Cell Lung Cancer

Chandler, Arizona
Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

672 Participants Needed

EGFR Inhibitor for Brain Cancer

Scottsdale, Arizona
This trial is testing a new drug called WSD0922-FU for patients with aggressive brain and spinal cord cancers. The drug works by blocking a protein that helps cancer cells grow. The goal is to find the best dose and see if it can effectively treat these hard-to-treat cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

55 Participants Needed

LYL797 for Breast and Lung Cancer

Scottsdale, Arizona
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

100 Participants Needed

Selpercatinib for Solid Tumors

Scottsdale, Arizona
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+

857 Participants Needed

AU-007 for Advanced Cancer

Scottsdale, Arizona
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

159 Participants Needed

Why Other Patients Applied

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"My mom has cholangiocarcinoma with bone mts (FGFR2 mutation). She really needs this trial to survive. She’s active and her analysis is ok, but we have very limited other options. Hope to work with a high-quality clinic to prolong her quality and duration of life."

OF
Cholangiocarcinoma PatientAge: 54

"I had two chemotherapy regímens without success, three surgeries during which the tumor could not be resected. These clinical trials are a light of hope for me and my family (I have a five year old child) and I have read about cases of success in other types of cancer with this treatment. I think that I am a perfect candidate for this tríal. Thank you."

UM
Pancreatic Cancer PatientAge: 48

"I've had radiation and as far as I know I’m in remission, but my brother passed away with the same condition. I don’t mind helping research for a cure... my husband passed away with pancreatic cancer. I've had a stepdaughter that passed away with ovarian cancer at 20. I just think it’s time to knock cancer out! I'd really like to help find better treatments by participating in a trial."

EQ
Lung Cancer PatientAge: 70

"I've tried chemotherapy and radiation but the cancer recurred. My oncologist suggested that I might want to try a clinical trial given my situation. Just starting to research, hoping to learn more."

FR
Lung Cancer PatientAge: 71

CYT-0851 for Cancer

Scottsdale, Arizona
This trial is testing a new drug called CYT-0851 in patients with certain types of cancer that have not responded to other treatments. The goal is to see if the drug is safe and understand how it works in the body.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

170 Participants Needed

HFB200301 + Tislelizumab for Advanced Cancers

Scottsdale, Arizona
This trial tests a new drug, HFB200301, alone and with another drug, tislelizumab, in adults with advanced cancers. Researchers will start with a low dose and gradually increase it to find the most suitable amount. They will then test this amount in more patients to see how well it works against different cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

170 Participants Needed

DS-1062a vs Docetaxel for Lung Cancer

Chandler, Arizona
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

605 Participants Needed

Atezolizumab + Tiragolumab for Lung Cancer

Gilbert, Arizona
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

829 Participants Needed

A2B395 CAR T-Cell Therapy for Colorectal Cancer

Gilbert, Arizona
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

240 Participants Needed

BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

Gilbert, Arizona
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

200 Participants Needed

BAY2927088 for Non-Small Cell Lung Cancer

Gilbert, Arizona
This trial is testing a new drug called BAY2927088 for people with advanced lung cancer. The drug aims to block certain proteins that help cancer grow. Researchers want to find out how safe the drug is, the best dose to use, and how well it works in stopping cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

370 Participants Needed

Patritumab Deruxtecan for Non-Small Cell Lung Cancer

Gilbert, Arizona
This trial is testing a new drug called patritumab deruxtecan for patients with advanced lung cancer who have specific genetic mutations and have not responded to other treatments. The drug targets cancer cells specifically and delivers chemotherapy directly to them.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

277 Participants Needed

Pembrolizumab Combinations for Small Cell Lung Cancer

Gilbert, Arizona
This trial tests a combination of pembrolizumab and new experimental drugs in patients with advanced lung cancer who did not respond to previous treatments. The goal is to see if this combination is safe and effective. Pembrolizumab helps the immune system attack cancer by blocking a protein that stops immune cells from working. Pembrolizumab has been widely studied and approved for the treatment of various cancers, including lung cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

110 Participants Needed

Pembrolizumab + Chemotherapy for Small Cell Lung Cancer

Gilbert, Arizona
This trial is testing new drugs combined with existing treatments and chemotherapy to see if they can better treat patients with severe, widespread lung cancer by boosting the immune system and enhancing chemotherapy effects.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

120 Participants Needed

123456

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Lung Cancer clinical trials in Glendale, AZ pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Lung Cancer clinical trials in Glendale, AZ work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Lung Cancer trials in Glendale, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Glendale, AZ for Lung Cancer is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Glendale, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Lung Cancer medical study in Glendale, AZ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Lung Cancer clinical trials in Glendale, AZ?

Most recently, we added Multiple Treatments for Non-Small Cell Lung Cancer, A2B395 CAR T-Cell Therapy for Colorectal Cancer and CLSP-1025 for Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Arizona

Anxiety Clinical Trials in Arizona

Schizophrenia Clinical Trials in Arizona

ADHD Clinical Trials in Arizona

Bipolar Disorder Clinical Trials in Arizona

Multiple Sclerosis Clinical Trials in Arizona

Autism Clinical Trials in Arizona

Treatment Resistant Depression Clinical Trials in Arizona

Borderline Personality Disorder Clinical Trials in Arizona

Social Anxiety Disorder Clinical Trials in Arizona

Parkinson's Disease Clinical Trials in Arizona

Alzheimer's Disease Clinical Trials in Arizona

By Location

Clinical Trials near Phoenix, AZ

Clinical Trials near Tucson, AZ

Clinical Trials near Scottsdale, AZ

Clinical Trials near Mesa, AZ

Clinical Trials near Chandler, AZ

Clinical Trials near Tempe, AZ

Clinical Trials near Gilbert, AZ

Clinical Trials near Glendale, AZ

Clinical Trials near Peoria, AZ

Clinical Trials near Sun City, AZ

Clinical Trials near Goodyear, AZ

Clinical Trials near Flagstaff, AZ

Other People Viewed

By Subject

Top Breast Cancer Clinical Trials near Glendale, AZ

Top Prostate Cancer Clinical Trials near Glendale, AZ

Top Clinical Trials near Glendale, AZ

Top Clinical Trials near Glendale, AZ

Top Colorectal Cancer Clinical Trials near Glendale, AZ

Top Lung Cancer Clinical Trials near Phoenix, AZ

12 Weight Loss Trials near Glendale, AZ

Top Post-Traumatic Stress Disorder Clinical Trials near Glendale, AZ

Top Colorectal Cancer Clinical Trials near Phoenix, AZ

Top Breast Cancer Clinical Trials near Phoenix, AZ

Top Prostate Cancer Clinical Trials near Phoenix, AZ

Top Lung Cancer Clinical Trials near Columbia, SC

By Trial

Acupuncture for Lung Cancer

Grape Seed Extract for Early Stage Lung Cancer

REGN5093-M114 for Non-Small Cell Lung Cancer

Pulmonary Rehabilitation for Lung Cancer

Radiation + Immunotherapy for Non-Small Cell Lung Cancer

Onvansertib for Small Cell Lung Cancer

IRDye800CW-nimotuzumab Imaging for Lung Cancer Surgery

Enhanced Screening for Lung Cancer

TATE + Pembrolizumab for Lung Cancer

Durvalumab + Radiation for Lung Cancer

Certolizumab + Chemotherapy + Nivolumab for Lung Cancer

Centralized Care Strategy for Smoking and Lung Cancer Screening

Related Searches

Top Lung-cancer Clinical Trials near Baltimore, MD

Top Clinical Trials near New York, NY

IASD System II Implant for Heart Failure

Oxaloacetate for Chronic Fatigue Syndrome

Tislelizumab + Pamiparib for Cancer

Continuous Glucose Monitoring for Type 2 Diabetes

Weekly vs Daily Insulin for Type 2 Diabetes

Mobile App for Cancer

Speech Therapy for Speech Sound Disorder

Mindfulness Training for Burnout

Lavender Aromatherapy for Anxiety During Skin Cancer Surgery

Rimegepant for Pediatric Migraine

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial